智通财经APP讯，方正证券(601901.SH)公告，公司近日收到中国证券监督管理委员会《关于同意方正 证券股份有限公司向专业投资者公开发行公司债券注册的批复》。该批复同意公司向专业投资者公开发 行面值总额不超过300亿元公司债券，有效期为自同意注册之日起24个月，公司在注册有效期内可以分 期发行。 ...

方正证券(601901.SH)公告，公司近日收到中国证券监督管理委员会《关于同意方正证券股份有限公司 向专业投资者公开发行公司债券注册的批复》。该批复同意公司向专业投资者公开发行面值总额不超过 300亿元公司债券，有效期为自同意注册之日起24个月，公司在注册有效期内可以分期发行。 ...

方正证券股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司近日收到中国证券监督管理委员会《关于同意方正证券股份有限公司向 专业投资者公开发行公司债券注册的批复》（证监许可〔2025〕2416 号）。该批 复同意公司向专业投资者公开发行面值总额不超过 300 亿元公司债券，有效期为 自同意注册之日起 24 个月，公司在注册有效期内可以分期发行。 公司将按照有关法律法规和上述批复的要求及公司相关授权，办理本次向专 业投资者公开发行公司债券相关事宜，并及时履行信息披露义务。 特此公告。 证券代码：601901 证券简称：方正证券 公告编号：2025-043 方正证券股份有限公司 关于获准向专业投资者公开发行公司债券的公告 2025 年 11 月 17 日 ...

人民财讯11月17日电，方正证券(601901)11月17日公告，公司近日收到中国证券监督管理委员会《关于 同意方正证券股份有限公司向专业投资者公开发行公司债券注册的批复》。该批复同意公司向专业投资 者公开发行面值总额不超过300亿元公司债券，有效期为自同意注册之日起24个月，公司在注册有效期 内可以分期发行。 ...

每经AI快讯，11月17日，方正证券(601901.SH)公告称，公司近日收到中国证券监督管理委员会批复， 同意公司向专业投资者公开发行面值总额不超过300亿元公司债券，有效期为自同意注册之日起24个 月，公司在注册有效期内可以分期发行。 ...

公司公告汇总关于获准向专业投资者公开发行短期公司债券的公告 方正证券近日收到中国证券监督管理委员会批复，同意公司向专业投资者公开发行短期公司债券，面值 余额不超过50亿元，注册有效期为24个月，可分期发行。公司将按相关规定办理发行事宜并履行信息披 露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：11月14日主力资金净流出1372.87万元，占总成交额2.46%。 来自公司公告汇总：方正证券获证监会批复，同意公开发行面值不超过50亿元的短期公司债券。 截至2025年11月14日收盘，方正证券(601901)报收于8.26元，下跌0.24%，换手率0.82%，成交量67.5万 手，成交额5.59亿元。 当日关注点 交易信息汇总资金流向 11月14日主力资金净流出1372.87万元，占总成交额2.46%；游资资金净流入1095.95万元，占总成交额 1.96%；散户资金净流入276.92万元，占总成交额0.5%。 ...

公司公告汇总 方正证券近日收到中国证券监督管理委员会批复，同意公司向专业投资者公开发行短期公司债券，面值 余额不超过50亿元，注册有效期为24个月，可分期发行。公司将按相关规定办理发行事宜并履行信息披 露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：方正证券获证监会批复，可向专业投资者公开发行面值余额不超过50亿元的短期 公司债券。 截至2025年11月14日收盘，方正证券（601901）报收于8.26元，较上周的8.28元下跌0.24%。本周，方 正证券11月10日盘中最高价报8.4元。11月12日盘中最低价报8.19元。方正证券当前最新总市值679.97亿 元，在证券板块市值排名14/50，在两市A股市值排名256/5165。 ...

Core Insights - The brokerage business has shown remarkable performance in the third quarter of 2025, becoming a significant driver of revenue growth for listed brokerages [1][2] - The transformation towards wealth management is timely as retail investors increasingly allocate assets to equity markets, emphasizing the need for brokerages to enhance their professional service capabilities [1][3] Group 1: Brokerage Business Performance - In the first three quarters, 42 brokerages reported a total net income from brokerage fees of 111.77 billion yuan, marking a year-on-year increase of 74.64% [1] - Leading firms such as CITIC Securities and Guotai Junan achieved net income from brokerage fees exceeding 10 billion yuan, with figures of 10.939 billion yuan and 10.814 billion yuan respectively [1] - Other notable brokerages like GF Securities, China Merchants Securities, Huatai Securities, and others also reported net income from brokerage fees exceeding 6 billion yuan [1] Group 2: Growth Rates and Market Dynamics - All listed brokerages reported year-on-year growth in net income from brokerage fees, with the lowest growth rate being 47.91% [2] - Guolian Minsheng led the industry with a staggering year-on-year growth rate of 293.05% in net income from brokerage fees [2] - Smaller brokerages such as First Capital, Caida Securities, and others also reported growth rates exceeding 80% [2] Group 3: Wealth Management Transformation - The securities industry has been actively pursuing wealth management transformation since 2017, with many brokerages rebranding their brokerage departments to focus on wealth management [3] - Despite facing challenges in product and service offerings compared to banks, brokerages possess strong investment capabilities and research strengths, providing them with advantages in wealth management [3] - The construction of product platforms is seen as a critical breakthrough for the transformation of wealth management [3] Group 4: Strategic Initiatives by Brokerages - First Capital is focusing on a comprehensive service model to enhance customer loyalty and mitigate fee pressure through improved service quality [4] - GF Securities aims to develop high-quality customer segments and efficient online operations while enhancing multi-asset allocation capabilities [4] - Dongxing Securities emphasizes a "buy-side" approach in its wealth management strategy, aiming to strengthen its operational capabilities and product offerings [4]

Core Points - The company, Fangzheng Securities, has received approval from the China Securities Regulatory Commission to publicly issue short-term corporate bonds to professional investors [2] - The total face value of the bonds will not exceed 5 billion yuan, with a validity period of 24 months from the date of approval [2] - The company plans to issue the bonds in installments during the registration validity period and will comply with relevant laws and regulations [2]

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]